The New NHS Injection for Weight Loss: What's Actually Happening

Which injections has the NHS actually approved for weight loss?

The two medicines driving this conversation are tirzepatide, sold under the brand name Mounjaro, and semaglutide, sold as Wegovy. Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) to reduce appetite and slow gastric emptying; semaglutide targets the GLP-1 receptor alone. Both are once-weekly subcutaneous injections, and both are licensed in the UK specifically for weight management in adults, not for cosmetic weight loss, not for people who just want to shift a few pounds.

NICE recommended tirzepatide for NHS use in December 2024 (guidance TA1026). Semaglutide (Wegovy) had already been recommended earlier, under NICE guidance TA875, though that recommendation tied access to specialist weight management services with multidisciplinary support. The practical effect: waiting lists for Wegovy on the NHS have been long in many areas. If you want a fuller picture of how these approvals have unfolded and what they mean for patients, our page on new weight loss injections on the NHS covers the tirzepatide rollout in detail, including the phased approach and why not everyone can access it yet.

One thing worth clarifying: Ozempic is also semaglutide, but it carries a different UK licence, for type 2 diabetes, not weight management. It is not the medicine being discussed when people talk about the new NHS weight loss injection.

Who actually qualifies for tirzepatide on the NHS right now?

This is a question our prescribers hear most weeks, and the honest answer has changed as phases have activated. NHS England's rollout of tirzepatide under NICE TA1026 is tied to BMI thresholds and the number of qualifying weight-related conditions a person has. The five recognised conditions are: high blood pressure, dyslipidaemia (abnormal blood fats), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.

From June 2025, the first cohort covered adults with a BMI of 40 or above plus four or more of those five conditions. From June 2026 (specifically, 23 June 2026) Cohort 2 opened access to people with a BMI of 35–39.9 alongside the same four-or-more-conditions threshold. A further phase, expected around March 2027, will extend to BMI 40-plus with three qualifying conditions. Throughout, BMI thresholds are reduced by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

Meeting the criteria on paper doesn't guarantee a prescription, either. Every NHS patient must be enrolled in wraparound diet and activity support, and GP participation in the new prescribing pathway is optional, so access varies by area. You can use the NHS BMI calculator to check your figure; our guide to BMI thresholds for NHS weight loss injections goes into the qualifying conditions in more detail.

What if you don't qualify for the NHS route, or simply can't wait?

A significant number of people fall just outside the NHS criteria: BMI of 32, one qualifying condition, no realistic prospect of hitting Cohort 3. Others technically qualify but face a six-month wait at their practice or have a GP who isn't participating in the new prescribing pathway. Both situations are common and completely understandable.

Private prescription is the legal alternative. Through a GPhC-registered online pharmacy, you can access the same licensed UK medicines (Mounjaro and Wegovy) following a clinical assessment by a prescriber who holds a GPhC Independent Prescriber qualification. The private eligibility criteria follow the medicines' UK licences: broadly, adults with a BMI of 30 or above, or 27-plus with at least one weight-related condition. A prescriber looks at the full clinical picture; BMI alone doesn't decide suitability either way.

For context on what private treatment typically costs, our overview of weight loss injections explains what a legitimate private price should include, consultation, prescription, dispensing, delivery and aftercare. If you're comparing providers, our page on what 'cheap' weight loss injections actually means is worth reading before you make any decisions.

There is no shortcut that bypasses clinical assessment. These are Prescription-Only Medicines; anyone offering them without one (via social media, without a consultation, at prices far below market) is selling something that may not be what it claims to be. The MHRA has warned publicly about counterfeit weight loss pens entering the UK supply chain and accepts reports of suspect sellers via the Yellow Card scheme. Verifying that an online pharmacy appears on the GPhC's public register before ordering is a straightforward step that takes under a minute.

What happens after you start treatment, NHS or private?

Both routes begin at a low starting dose (2.5mg for tirzepatide, 0.25mg for semaglutide) to let your system adjust before the dose is increased. That titration happens in roughly four-week steps and is managed by your prescriber, not by you working through a chart alone. Side effects are mostly gastrointestinal: nausea, changes in bowel habit, indigestion, and sometimes fatigue, particularly in the first week or two after a dose increase. Most people find these settle as the body acclimates.

For anyone currently exploring the NHS route or weighing it against private treatment, our page on getting a weight loss injection on the NHS sets out the referral and eligibility process in detail, and our step-by-step guide to accessing the new weight loss injection covers both routes side by side. If you'd like to talk through private treatment with our clinical team, the place to start is a free consultation, details of what that involves are on our treatment page.